Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Dantrolene sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Dantrium is a medicine that reduces increased muscle tension. Dantrium is used for spastic movement disorders with abnormally increased muscle tension due to various causes in adults and children over the age of 5 years old weighing 25 kg or more.
e Dantrium Capsules
Do not take Dantrium
if you have liver disease, –
in cases where abnormally increased muscle tension is required to improve function, posture or movement balance,
–
if you have impaired lung function,
–
if you have severe heart muscle damage,
–
if you are pregnant or breast-feeding,
–
If you are allergic (hypersensitive) to wheat, due to the presence of wheat starch.
Warnings and precautions Talk to your doctor or pharmacist before taking Dantrium.
1
Take special care with Dantrium
if you have heart disease, particularly heart damage and/or heart arrhythmia. Your doctor will carefully monitor you for heart disease.
Before and during treatment with Dantrium your doctor will carry out regular blood tests to check your liver function. If the values are outside the normal range, treatment with Dantrium must be discontinued. If you notice any signs that might indicate liver damage, such as unusual fatigue, light stools, itching all over the body, yellowing of the skin or eyes, loss of appetite, nausea and vomiting, you should seek medical attention immediately. The risk of liver damage appears to be particularly high at daily doses of more than 300 mg, with prolonged treatment, in female patients over 30 years of age, with a history of liver damage and concomitant use of other medicines that can cause liver damage. Liver damage can be life-threatening, especially in the elderly. If you suffer from multiple sclerosis, the risk of serious liver damage appears to be even higher. Dantrium may cause the skin to become sensitive to light (photosensitisation), so you should protect yourself from strong sunlight during treatment. Administration of Dantrium must be discontinued if patients have developed cardiac and pleural reactions with fluid accumulation (pleural or pericardial effusion or pleuropericarditis). Doses of more than 200 mg dantrolene per day are more likely to cause side effects. This medicine contains only very low levels of gluten (from wheat starch). It is regarded as 'glutenfree' and is very unlikely to cause problems if you have coeliac disease. One Dantrium 25mg capsule contains no more than 3.8 micrograms of gluten. One Dantrium 100mg capsule contains no more than 3.3 micrograms of gluten. Children Dantrium can be used in children over 5 years of age under supervision from your doctor. Dantrium should not be given to children under 5 years of age as there is insufficient experience with the use of Dantrium in this patient group to determine tolerability. Other medicines and Dantrium Tell your doctor or pharmacist if you are taking/using or have recently taken/used any other medicines, even if they are not prescription medications. If taken at the same time as –
oestrogens (certain hormones) or other potentially liver-damaging substances there is an increased risk of liver damage,
–
vecuronium (muscle relaxant drug) its effect can be amplified,
–
metoclopramide (a medicine used to treat certain gastrointestinal disorders), the absorption of the active ingredient of Dantrium in the body may be increased, leading to an increase in the effect and side effects of dantrolene.
2
Simultaneous use of medicines that depress the central nervous system (sedatives, such as benzodiazepines, antihistamines) and alcohol is to be avoided as the side effects of Dantrium may be increased (in particular the central nervous system depressant effect and muscle weakness). In patients predisposed to malignant hyperthermia (certain complications of anaesthesia) who received intravenous dantrolene, it has been observed that simultaneous administration of calcium antagonists and/or beta-blockers (antihypertensive/heart disease drugs) resulted in elevated potassium levels and cardiac insufficiency. Dantrium with food and drink Do not drink alcohol while taking Dantrium. Pregnancy and breast-feeding Dantrium should not be used during pregnancy, as the safety of Dantrium for use during pregnancy has not been established. The active substance of Dantrium passes into breast milk. Dantrium should not be used while breastfeeding, since adverse effects on the breastfed child cannot be excluded, particularly under long-term treatment with Dantrium. Breast-feeding must be discontinued if treatment is required while breastfeeding. Ask your doctor or pharmacist for advice before taking/using any medicine. Driving and using machines You must not drive or operate machinery without consulting your doctor. When Dantrium or other medicines that also affect the central nervous system are taken at the same time, central nervous system effects, such as drowsiness or confusion, can change the ability to react to such an extent that it reduces the ability to drive or operate tools and machines. This particularly applies at the start of treatment, when dosage is increased and when taken together with alcohol. Dantrium Capsules contain lactose and wheat starch. This medicine contains lactose and wheat starch. If you have been told by your doctor that you have an intolerance to some sugars, speak to your doctor before taking this medicine.
Dantrium Capsules Always take Dantrium exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will slowly adjust the number of capsules you take until the optimal dose required for your treatment is reached. The lowest dose compatible with optimal response is recommended. Adults Unless prescribed otherwise by your doctor, the usual dose for adults at the beginning of treatment is 1 capsule daily. This dose should be increased weekly until the optimal dose is reached. The dose should not be increased faster than as per the following schedule: Week 1: 1 Dantrium 25 mg capsule once a day Week 2: 1 Dantrium 25 mg capsule two times a day
3
Week 3: 2 Dantrium 25 mg capsules two times a day Week 4: 2 Dantrium 25 mg capsules three times a day Once the optimal dose is reached, the patient should take their total daily dose subdivided between 2 to 4 individual doses. Doses of more than 200 mg should not be given in long-term Dantrium treatment, as doses of more than 200 mg of dantrolene per day are more likely to result in side effects. If it is foreseeable that the patient will face stress or stressful situations, the dose can be increased temporarily and gradually up to 400 mg per day. The increased dose should be titrated as follows: Week 5: 75 mg three times a day Week 6: 75 mg four times a day Week 7: 100 mg four times a day Doses of more than 200 mg per day should not be given for more than 2 months.
Children Unless prescribed otherwise by your doctor, the following dosage should be used for children aged 5 years and older (from 25 kg body weight): Week 1: 1 Dantrium 25 mg capsule once a day Week 2: 1 Dantrium 25 mg capsule two times a day Week 3: 1 Dantrium 25 mg capsule three times a day Week 4: 2 Dantrium 25 mg capsules two times a day Week 5: 2 Dantrium 25 mg capsules three times a day Week 6: 3 Dantrium 25 mg capsules three times a day Children weighing 50 kg or more: See dosage for adults. The dose can be gradually increased up to 200 mg daily. Please take the capsules whole with plenty of liquid (preferably with a glass of water). If no improvement is achieved after a total of 6-8 weeks, treatment should be discontinued by the doctor. Please talk to your doctor or pharmacist if you feel that the effect of Dantrium is too strong or too weak. If you take more Dantrium than you should Tell your doctor immediately. He or she will take the necessary measures. Signs of overdose may include disorders of consciousness (e.g. lethargy, coma), muscle weakness, fatigue, dizziness, weakness, impaired vision, rapid heartbeat, itching, loss of appetite, nausea, vomiting, diarrhoea, light stools, yellowing of the skin or eyes.
4
If you forget to take Dantrium Do not take a double dose to make up for an omitted dose. Take the same number of capsules as prescribed, when your next dose is due. If you are unsure what to do, please talk to your doctor. If you stop taking Dantrium If you temporarily want to stop treatment or stop it early, e.g. because the side effects appear too severe, please talk to your doctor first. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The frequencies for the following list of adverse drug reactions are based on estimates after reports of adverse drug reactions to the approved drug. Very common (may affect more than 1 in 10 people): Fatigue, weakness, malaise, dizziness, drowsiness and diarrhoea. In persistent diarrhoea, the medicinal product must be discontinued. Common (may affect up to 1 in 10 people): In patients treated with Dantrium, the following occurred: Headache, speech disorders, seizures, loss of appetite, impaired vision, abdominal cramps, nausea, vomiting, skin rashes, acne-like skin reactions, muscle weakness, which may cause functional impairment and coordination disorders, chills, fever, depression, confusion, nervousness, insomnia, respiratory failure, abnormal liver function test, liver damage: even daily doses of up to 200 mg can cause liver-damaging side effects, usually as inflammation of the liver with jaundice. Uncommon (may affect up to 1 in 100 people): In patients treated with Dantrium, the following occurred: Reduction of red blood cells due to impaired or lack of production (aplastic anaemia), reduction of white blood cells (leukopaenia), lymph node cancer (lymphocytic lymphoma), thrombocytopaenia, allergic reaction, acute allergic reaction (anaphylaxis), hallucinations, triggering of cerebral seizures, particularly in children with cerebral palsy; aggravation of paralysis in amyotrophic lateral sclerosis (ALS, a disorder of the nervous system) or presence of symptoms of bulbar paralysis (symptoms caused by damage to certain cranial nerves). Double vision, increased tear-flow, increased heart rate, insufficient cardiac output (heart failure); phlebitis, fluctuations in blood pressure, constipation, in rare cases including intestinal obstruction; difficulty swallowing, taste disorders, shortness of breath, bleeding in the gastrointestinal tract, abdominal pain, increased salivation. Increased sweating, abnormal hair growth, itching, photosensitivity, muscle and back pain, excretion of crystals or red blood cells in the urine (crystalluria, haematuria), involuntary urinary incontinence, urinary retention or increased urinary frequency, Cardiac and pleural reactions with fluid accumulation (pleural or pericardial effusion or pleuropericarditis), accompanied by eosinophilia (proliferation of certain cells in the blood) has been reported, as well as respiratory disorders, presumably due to weakening of the respiratory muscles. Very Rare Feeling of suffocation, skin rash with red swollen bumps, eczema, Micturition disorder, erectile dysfunction. Not known (frequency cannot be estimated from the available data): Decreased heart rate, disorientation. Reduced muscle tone, dry mouth, nocturnal urination (nocturia), discoloured urine, indigestion.
5
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Dantrium Capsules Keep out of the sight and reach of children. Store capsules in the blister and outer packaging away from light and moisture. Do not take Dantrium Capsules after the expiry date which is stated on the outer carton and the blister after "Exp". The expiry date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
What Dantrium Capsules contain
6
This leaflet was last revised in 03/2025.
7
Dantrium 25mg Capsules comes as capsule containing 25mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Dantrium 25mg Capsules is dantrolene sodium.
This leaflet reproduces the patient information leaflet approved for Dantrium 25mg Capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Dantrium capsules are indicated for the treatment of chronic, severe spasticity of skeletal muscle resulting from disorders such as stroke, spinal cord injury, cerebral palsy and multiple sclerosis in adults and children over the age of 5 years old weighing 25 kg or more.
Posology
Each patient should be slowly titrated to the required individual dose. For the individual patient the lowest dose compatible with optimal response is recommended. A recommended dosage increment scale is shown below.
Adults:
Dantrium should be titrated no more rapidly than as per the following schedule:
Week 1: 25 mg once a day
Week 2: 25 mg two times a day
Week 3: 50 mg two times a day
Week 4: 50 mg three times a day
As soon as the optimal dose is reached, patients should receive their total daily dose divided over 2 to 4 individual doses to achieve as uniform plasma levels as possible and to minimise adverse reactions.
Doses higher than 200 mg should not be administered in long-term therapy with Dantrium. Temporarily, the dose can be gradually increased up to 400 mg per day if pressurised or stressful situations are anticipated in the patient. The increased dose should be titrated as follows:
Week 5: 75 mg three times a day
Week 6: 75 mg four times a day
Week 7: 100 mg four times a day
However, doses above 200 mg per day should not be given for more than 2 months.
Paediatric Population
Dosing table for children over 5 years (upwards of 25 kg body weight) For the individual patient the lowest dose compatible with optimal response is recommended. A recommended dosage titration schedule is provided below.
Week 1: 1 Dantrium 25 mg capsule once a day
Week 2: 1 Dantrium 25 mg capsule two times a day
Week 3: 1 Dantrium 25 mg capsule three times a day
Week 4: 2 Dantrium 25 mg capsules two times a day
Week 5: 2 Dantrium 25 mg capsules three times a day
Week 6: 3 Dantrium 25 mg capsules three times a day
For children weighing 50 kg or more, see dosage for adults.
The dose can be increased gradually up to 200 mg daily.
Dantrium is intended for long-term therapy.
If therapeutic success is still absent after 6 - 8 weeks of treatment, therapy should be discontinued.
As there is insufficient experience with the use of Dantrium in children under 5 years to assess its tolerability, it should not be used in this patient group.
Method of administration
For oral use.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Hepatic disorders,
- Impaired respiratory function
- Severe impaired cardiac function due to myocardial disease
- In cases where abnormally increased tone is required to allow better function, an upright posture or balance during movement.
- Pregnancy and breastfeeding (see section 4.6)
- Wheat allergy (other than coeliac disease), (see section 4.4).
Dantrium must be used with caution in the following situations:
In cases of amyotrophic lateral sclerosis or in the presence of bulbar paralytic symptoms, as paresis can be enhanced by Dantrium.
Patients with cardiac disease, especially in patients with myocardial damage and/or cardiac arrhythmias, must receive particular medical surveillance.
Dantrolene leads to mild to severe liver damage in about 9 out of 100,000 treated patients, in whom mortality affects 10 to 20%.
The risk of liver damage seems to be particularly increased at daily doses higher than 300 mg, during prolonged therapy, in women, in patients over 30 years of age or with a history of liver damage and during concomitant use of other medicinal products that can damage the liver. Liver damage may run a lethal course, especially in elderly patients. In patients suffering from multiple sclerosis, the risk of serious liver damage seems to be further increased.
Before the start and during therapy with Dantrium, liver enzymes must be monitored at regular intervals; in particular, SGOT and SGPT must be monitored frequently. Patients in whom the risk of liver damage is increased must receive particularly close monitoring. If values are outside the norm or if symptoms of liver damage occur, Dantrium must be discontinued.
There are indications that, when liver damage occurs, high serum bilirubin levels correlate to severe progression.
To reduce the risk of liver damage, the lowest possible effective dantrolene dose must be used.
Dantrium can cause photosensitisation; patients should therefore protect themselves against strong sunlight during treatment.
Dantrium must be discontinued if patients have developed pleural or pericardial effusion or pleuropericarditis.
Patients with rare hereditary problems of galactose intolerance, the lactase deficiency or glucose-galactose malabsorption should not take Dantrium.
At doses above 200 mg dantrolene per day, increased adverse reactions must be anticipated.
This medicine contains only very low levels of gluten (from wheat starch). It is regarded as 'gluten-free' and is very unlikely to cause problems in case of coeliac disease.
One capsule contains no more than 3.8 micrograms of gluten.
Concomitant intake of CNS depressants (such as benzodiazepine-type tranquillisers, antihistamines, sedatives) and alcohol consumption should be avoided, as the adverse reactions to Dantrium may be increased (particularly the depressant effect on the central nervous system and muscle weakness).
With concomitant administration of:
-oestrogens or other potentially hepatotoxic substances, there is an increased risk of liver damage.
-Dantrium and non-depolarising muscle relaxants (vecuronium), its effect can be enhanced.
-metoclopramide, the rate and speed of dantrolene absorption may be increased and thus lead to an increase in the effect and undesirable effects of dantrolene.
In patients predisposed to malignant hyperthermia who were receiving intravenous dantrolene, it was observed that co-administration of calcium antagonists and/or beta-blockers led to hyperkalaemia and heart failure.
Pregnancy
There are no or limited amount of data from the use of dantrolene sodium in pregnant women. Dantrolene crosses the placenta and can induce muscle hypotonia, especially in the uterus. Studies in animals are insufficient with respect to reproductive toxicity (see section 5.3). The use of Dantrium during pregnancy is contraindicated.
Breastfeeding
Dantrium is contraindicated during breastfeeding, as the active substance, dantrolene, is excreted in human milk and undesirable effects on the breast-fed infant cannot be excluded, particularly during long-term therapy with Dantrium. If treatment of nursing mothers with Dantrium is required, breastfeeding must be discontinued.
Fertility
There is no data on the effects of dantrolene on fertility in humans.
During oral use of Dantrium, central nervous effects such as drowsiness or confusion can alter responsiveness to such an extent that the ability to drive actively or operate tools and machinery is reduced. This applies particularly at the start of treatment, when increasing the dose and in combination with alcohol or other medicinal products that depress the central nervous system.
Tabulated list of adverse reactions
System Organ Class
Frequency
Adverse Drug Reactions
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uncommon
Lymphocytic lymphoma
Uncommon
Lymphoma
Blood and lymphatic system disorders
Uncommon
Aplastic anaemia
Uncommon
Anaemia
Uncommon
Leukopenia
Uncommon
Thrombocytopenia
Immune system disorders
Uncommon
Hypersensitivity
Uncommon
Anaphylactic reaction
Metabolism and nutrition disorders
Common
Decreased appetite
Psychiatric disorders
Common
Depression
Common
Confusional state
Common
Nervousness
Uncommon
Hallucination
Common
Insomnia
Unknown
Disorientation
Nervous system disorders
Very common
Dizziness
Very common
Somnolence
Common
Headache
Common
Speech disorder
Common
Seizures
Uncommon
Enhanced paresis in cases of amyotrophic lateral sclerosis or in the presence of bulbar paralytic symptoms
Uncommon
Dysgeusia
Unknown
Hypotonia
Eye disorders
Uncommon
Diplopia
Uncommon
Lacrimation increased
Common
Visual impairment
Cardiac disorders
Uncommon
Tachycardia
Uncommon
Cardiac failure
Common
Pericarditis
Uncommon
Pleuropericarditis
Unknown
Bradycardia
Vascular disorders
Uncommon
Phlebitis
Uncommon
Blood pressure fluctuation
Respiratory, thoracic and mediastinal disorders
Common
Respiratory depression
Common
Respiratory failure
Very rare
Suffocation feeling
Uncommon
Dyspnoea
Gastrointestinal disorders
Very Common
Diarrhoea
Common
Abdominal cramps
Common
Nausea
Common
Vomiting
Uncommon
Constipation (rarely progressing to signs of intestinal obstruction)
Uncommon
Dysphagia
Uncommon
Gastrointestinal haemorrhage
Uncommon
Abdominal pain upper
Uncommon
Salivary hypersecretion
Unknown
Dyspepsia
Unknown
Dry Mouth
Hepatobiliary disorders
Common
Hepatotoxicity/hepatitis
Common
Jaundice
Common
Cholestasis
Skin and subcutaneous tissue disorders
Common
Rash
Common
Dermatitis acneiform/acne like rash/acne
Uncommon
Hyperhidrosis
Uncommon
Hair growth abnormal
Uncommon
Pruritus
Uncommon
Photosensitivity reaction
Very rare
Urticaria
Very rare
Eczema
Musculoskeletal and connective tissue disorder
Common
Muscular weakness
Uncommon
Back pain
Uncommon
Myalgia
Renal and urinary disorders
Uncommon
Urinary incontinence
Uncommon
Pollakiuria
Uncommon
Crystalluria
Uncommon
Haematuria
Uncommon
Urinary retention
Unknown
Nocturia
Very rare
Micturition disorder
Unknown
Chromaturia
Reproductive system and breast disorders
Very rare
Erectile dysfunction
General disorders and administration site conditions
Very common
Fatigue
Very common
Malaise
Common
Chills
Common
Pyrexia
Very common
Asthenia
Investigations
Common
Liver function tests abnormal
In addition, the following specific undesirable effects have been noticed with the use of Dantrium Capsules:
- Precipitation of cerebral seizures, especially in children with cerebral palsy;
- pleuropericarditis and pericardial effusion, (accompanied by eosinophilia)
- pleural effusion (with associated eosinophilia),
- Diarrhoea (may be severe and may necessitate temporary withdrawal of dantrolene therapy).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms which may occur in case of overdose are: muscular weakness, troubling hypotonia vision disorders (diplopia), changes in consciousness (lethargy, coma), fatigue, dizziness vomiting, diarrhoea, tachycardia, hypo- or hypertension, pruritus, adverse hepatotoxic reactions.
In case of intoxication, if possible, gastric emptying should be performed and general measures for cardiac support and respiratory assistance should be planned. Dilution solution should be infused intravenously to avert the possibility of crystalluria.
The value of dialysis in dantrolene overdose is not known and there is no specific antidote for dantrolene overdose.
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Dantrium 25mg Capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.